October 2, 2014
Belviq – a new drug for hair loss
In the Recent decades a number of drugs had been introduced for weight loss but most of them were found to have side effects and therefore were banned for sale. For many years remained a single drug to treat weight loss – Xenical, which operates in the intestine and prevents the absorption of fats. However drugs that act on the mechanism of satiety and reduce overeating and therefore disqualified to use the emergence of new drugs and safe use of the line really is. It should be emphasized that the drug is not a magic wand at the same time it has to maintain proper eating and exercise to achieve a good result.
In 2012 presented a number of new drugs for FDA approval and many fortunes were two of them for approval: Blwik and charming. These drugs will be marketed first in the United States but is expected to come to Israel in the coming year. Article presents the first drug approved: Blwik.
In July 2012, the FDA for approval of a new drug called Blwik (Belviq- (lorcaserin hydrochloride for the treatment of obesity. This is the first drug approved for this purpose in the United States in 10 years. Drug is manufactured in Switzerland by Chabad of Arena Pharmaceuticals and should reduce food intake and give a feeling of satiety by activating serotonin receptors.
Dr. Janet Woodcock of the FDA noted that in light of the global obesity epidemic such an important drug in the market and along with good nutrition and a healthy lifestyle is to be able to provide a solution for obesity population.
The drug is approved for use in adults with BMI≥30, or BMI ≥27 with at least one comorbidity, such as hypertension, obesity, or type 2 diabetes.
The drug is approved for use after a series of three randomized clinical trials in which obese volunteers were tested received the drug or placebo, no patients or physicians know which drug was given volunteer. All studies included diet plan, moderate exercise, and behavioral counseling. A total of nearly 8,000 research volunteers between the ages of 16-65 who were followed up to two years.
The study showed that the volunteers who received the drug were able to reduce their weight on average 5% more than those who received the drug, when the drug administration was accompanied by diet and exercise. The volunteers were followed two years have also managed to maintain the weight loss.
The most common side effects among volunteers who do not have diabetes were: headache, dizziness, nausea, dry mouth, and constipation. For volunteers who have diabetes, the most common adverse events were: decrease of sugar (hypoglycemia), headache, back pain, cough, and fatigue.